Photo from Nancy Lin/X
May 19, 2024, 05:46
Nancy Lin: Updated data for Pfizer cdk4-selective inhibitor PF-07220060
Nancy Lin, Associate Chief of Division of Breast Oncology at Susan F. Smith Center for Women’s Cancers, shared on X:
“Updated data for Pfizer cdk4-selective inhibitor PF-07220060.
- patient population: 100% prior cdk4/6i
- favorable tox profile
- 32% ORR, median PFS 8.1 months
- efficacy regardless of ESR1 and PIK3CA mutation status.”
Source: Nancy Lin/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46
Nov 13, 2024, 15:32
Nov 13, 2024, 15:29
Nov 13, 2024, 15:25